|
1
|
Appel H, Kuhne M, Spiekermann S, et al:
Immunohistochemical analysis of hip arthritis in ankylosing
spondylitis: evaluation of the bone-cartilage interface and
subchondral bone marrow. Arthritis Rheum. 54:1805–1813. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chou CH, Lin MC, Peng CL, et al: A
nationwide population-based retrospective cohort study: increased
risk of acute coronary syndrome in patients with ankylosing
spondylitis. Scand J Rheumatol. 43:132–136. 2014. View Article : Google Scholar
|
|
3
|
Braun J and Sieper J: Ankylosing
spondylitis. Lancet. 369:1379–1390. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Thomas GP and Brown MA: Genomics of
ankylosing spondylitis. Discov Med. 10:263–271. 2010.PubMed/NCBI
|
|
5
|
Lories RJ and Baeten DL: Differences in
pathophysiology between rheumatoid arthritis and ankylosing
spondylitis. Clin Exp Rheumatol. 27(Suppl 55): S10–S14. 2009.
|
|
6
|
Tam LS, Gu J and Yu D: Pathogenesis of
ankylosing spondylitis. Nat Rev Rheumatol. 6:399–405. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Khan MA, Mathieu A, Sorrentino R and Akkoc
N: The pathogenetic role of HLA-B27 and its subtypes. Autoimmun
Rev. 6:183–189. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wei JC, Tsai WC, Lin HS, Tsai CY and Chou
CT: HLA-B60 and B61 are strongly associated with ankylosing
spondylitis in HLA-B27-negative Taiwan Chinese patients.
Rheumatology (Oxford). 43:839–842. 2004. View Article : Google Scholar
|
|
9
|
Diaz-Peña R, Blanco-Gelaz MA,
Suárez-Alvarez B, et al: Activating KIR genes are associated with
ankylosing spondylitis in Asian populations. Hum Immunol.
69:437–442. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kim TH, Stone MA, Rahman P, et al:
Interleukin 1 and nuclear factor-kappaB polymorphisms in ankylosing
spondylitis in Canada and Korea. J Rheumatol. 32:1907–1910.
2005.PubMed/NCBI
|
|
11
|
McGarry F, Neilly J, Anderson N, Sturrock
R and Field M: A polymorphism within the interleukin 1 receptor
antagonist (IL-1Ra) gene is associated with ankylosing spondylitis.
Rheumatology (Oxford). 40:1359–1364. 2001. View Article : Google Scholar
|
|
12
|
van Sijl AM, van Eijk IC, Peters MJ, et
al: Tumour necrosis factor blocking agents and progression of
subclinical atherosclerosis in patients with ankylosing
spondylitis. Ann Rheum Dis. 2013.Epub ahead of print. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Feldtkeller E and Braun J: Impact of sex
on inheritance of ankylosing spondylitis. Lancet. 355:1096–1097;
author reply 1098. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Davey-Ranasinghe N and Deodhar A:
Osteoporosis and vertebral fractures in ankylosing spondylitis.
Curr Opin Rheumatol. 25:509–516. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xu HF, Zhang L, Zhang Y and Chu TW:
Histopathologicai and ultra-structural observation of the
supraspinal ligaments in ankylosing spondylitis. Chinese Journal of
Rheumatology. 17:152–154. 2013.In Chinese.
|
|
16
|
Arnett FC, Edworthy SM, Bloch DA, et al:
The American Rheumatism Association 1987 revised criteria for the
classification of rheumatoid arthritis. Arthritis Rheum.
31:315–324. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Appel H, Loddenkemper C, Grozdanovic Z, et
al: Correlation of histopathological findings and magnetic
resonance imaging in the spine of patients with ankylosing
spondylitis. Arthritis Res Ther. 8:R1432006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pan X, Yue J, Ding G, et al: Leucine-rich
repeat 11 of Toll-like receptor 9 can tightly bind to
CpG-containing oligodeoxy-nucleotides, and the positively charged
residues are critical for the high affinity. J Biol Chem.
287:30596–30609. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Stone MA, Inman RD, Wright JG and Maetzel
A: Validation exercise of the Ankylosing Spondylitis Assessment
Study (ASAS) group response criteria in ankylosing spondylitis
patients treated with biologics. Arthritis Rheum. 51:316–320. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hreggvidsdottir HS, Noordenbos T and
Baeten DL: Inflammatory pathways in spondyloarthritis. Molecular
immunology. 57:28–37. 2014. View Article : Google Scholar
|
|
21
|
Gratacós J, Collado A, Filella X, et al:
Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in
ankylosing spondylitis: a close correlation between serum IL-6 and
disease activity and severity. Br J Rheumatol. 33:927–931. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Stone MA and Inman RD: The genetics of
cytokines in ankylosing spondylitis. J Rheumatol. 28:1203–1206.
2001.PubMed/NCBI
|
|
23
|
Massagué J, Blain SW and Lo RS: TGFbeta
signaling in growth control, cancer, and heritable disorders. Cell.
103:295–309. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Derynck R, Akhurst RJ and Balmain A:
TGF-beta signaling in tumor suppression and cancer progression. Nat
Genet. 29:117–129. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Blobe GC, Schiemann WP, Pepin MC, et al:
Functional roles for the cytoplasmic domain of the type III
transforming growth factor beta receptor in regulating transforming
growth factor beta signaling. J Biol Chem. 276:24627–24637. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kirkbride KC, Townsend TA, Bruinsma MW,
Barnett JV and Blobe GC: Bone morphogenetic proteins signal through
the transforming growth factor-beta type III receptor. J Biol Chem.
283:7628–7637. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ducy P, Starbuck M, Priemel M, et al: A
Cbfa1-dependent genetic pathway controls bone formation beyond
embryonic development. Genes Dev. 13:1025–1036. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Otto F, Thornell AP, Crompton T, et al:
Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is
essential for osteoblast differentiation and bone development.
Cell. 89:765–771. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Portal-Núñez S, Lozano D and Esbrit P:
Role of angiogenesis on bone formation. Histol Histopathol.
27:559–566. 2012.PubMed/NCBI
|
|
30
|
Clarkin CE and Gerstenfeld LC: VEGF and
bone cell signalling: an essential vessel for communication? Cell
Biochem Funct. 31:1–11. 2013. View
Article : Google Scholar
|
|
31
|
Maksymowych WP: Biomarkers in
spondyloarthritis. Curr Rheumatol Rep. 12:318–324. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Soliman E, Labib W, el-Tantawi G, Hamimy
A, Alhadidy A and Aldawoudy A: Role of matrix metalloproteinase-3
(MMP-3) and magnetic resonance imaging of sacroiliitis in assessing
disease activity in ankylosing spondylitis. Rheumatol Int.
32:1711–1720. 2012. View Article : Google Scholar
|
|
33
|
Arends S, van der Veer E, Groen H, et al:
Serum MMP-3 level as a biomarker for monitoring and predicting
response to etanercept treatment in ankylosing spondylitis. J
Rheumatol. 38:1644–1650. 2011. View Article : Google Scholar : PubMed/NCBI
|
